Skip to content
Screener

Biohaven BHVN Net Income

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$110.74M-30.7%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$56.62M-112%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$80.08M+172%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$43.4M-253%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.36M-75.1%

Segments

By segment

See full
Reportable Segment-$130.53M+41.1%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.17B+41.2%
Enterprise value$2.18B+31.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Biohaven’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001935979-26-000045
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other income, net168493
Loss before provision for income taxes(130,260)(221,068)
Provision for income taxes272609
Net loss$(130,532)$(221,677)
Net loss per share — basic and diluted$(0.88)$(2.17)
Weighted average common shares outstanding—basic and diluted147,615,197101,943,396
Comprehensive loss:
Net loss$(130,532)$(221,677)

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Biohaven's net income?
Biohaven (BHVN) reported net income of -$130.53M in Q1 2026.
How has Biohaven's net income changed year-over-year?
Biohaven's net income increased by 41.1% year-over-year, from -$221.68M to -$130.53M.
What is the long-term trend for Biohaven's net income?
Over 4 years (2021 to 2025), Biohaven's net income has grown at a 36.3% compound annual growth rate (CAGR), from -$213.8M to -$738.82M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Biohaven's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude